United Therapeutics Corp. ((UTHR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: United Therapeutics Corp. is conducting a study titled EXPAND: A Prospective Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With End-stage Renal Disease (ESRD). This study aims to assess the safety and efficacy of the 10 GE Xenokidney in patients with ESRD who are either ineligible for conventional kidney transplantation or are on a transplant waitlist with a high risk of not receiving a transplant within five years. The study’s significance lies in its potential to offer a new treatment option for patients with limited alternatives.
Intervention/Treatment: The intervention being tested is the 10 GE Xenokidney, a porcine-derived kidney with genomic alterations designed for xenotransplantation. This biological treatment aims to provide a viable transplant option for patients with ESRD.
Study Design: This interventional study follows a single-group model, enrolling participants from two specific patient populations. There is no allocation or masking involved, as the primary purpose is treatment. The study will evaluate the intervention’s efficacy and safety over a 24-week post-transplant period, followed by long-term follow-up.
Study Timeline: The study began on March 3, 2025, with the latest update submitted on August 25, 2025. These dates indicate the study’s progression and ongoing recruitment status, reflecting its current relevance and activity in the clinical research landscape.
Market Implications: The advancement of this study could positively impact United Therapeutics’ stock performance by showcasing innovation in the treatment of ESRD. Successful outcomes may enhance investor confidence and position the company favorably against competitors in the biotechnology sector, particularly in the niche of organ transplantation alternatives.
The study is ongoing, with further details available on the ClinicalTrials portal.